PhaseBio Pharmaceuticals Inc. (PHAS) PT Lowered to $17 at Stifel
Tweet
Share
E-mailGet Alerts PHAS Hot Sheet
Price: $0.07 --0%
Rating Summary:
2 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 24
Rating Summary:
2 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 24
Join SI Premium – FREE
Stifel analyst Adam Walsh lowered the price target on PhaseBio Pharmaceuticals Inc. (NASDAQ: PHAS) to $17.00 (from $20.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bernstein SocGen Group Upgrades Analog Devices (ADI) to Outperform
- Kingsoft Cloud (KC) PT Raised to $17.70 at Jefferies
- Morgan Stanley Upgrades Suncor Energy (SU) to Overweight
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
StifelSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
